XBiotech discontinues its phase III trial & more — 6 GI company key notes

Here are six updates on GI companies from the past week.

Advertisement

After early findings were “not sufficient to meet efficacy,” XBiotech discontinued the phase III study of its novel candidate antibody therapy for colorectal cancer.

Takeda Pharmaceuticals is relocating approximately 100 researchers to Boston during fiscal year 2017.

Boston Scientific is investing $19 million in a new Galway, Ireland-based RoadRunner endoscopy design facility.

The FDA awarded Becton, Dickinson and Company‘s BD Max’s extended enteric bacterial panel 510(k) clearance.

Level Ex CEO and Founder Sam Glassenberg is working to address how gastroenterologists can virtually practice their craft through the company’s app, GastroEx.

Numerate entered into an agreement with Takeda to use its artificial intelligence engines to develop clinical candidates in multiple specialties.

More articles on gastroenterology:
5 stats on GI net revenue per case at multispecialty ASCs
GI leader to know: Dr. Namita Pareek of Gastroenterology Associates of Gainesville
5 thoughts from a first-year GI fellow

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Unlocking Structural Heart Capacity: How Leading Programs Use EMR and Data to Improve Patient Flow and Throughput

Wednesday, August 19
11:00 AM - 12:00 PM CDT

Presenters: Katie Kennedy, MSN, APRN, NP-C, Community Heart and VascularMisty Theriot, BSN, RN, CPHQ, FACC, Lake Charles Memorial Health SystemKatie Worthington, DNP, RN, Atlantic Health SystemTaryn Shipley, MBA, CSSBB, Lean HealthTech

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.